The latest Russia Pharma News, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing, Geropharm’s deal to produce insulin in Venezuela, the bypassing of Gilead’s Remdesivir IP, and the Russian government’s decision to delay approvals of Chinese vaccines in favor of local shots.
Russian Biocad plans to produce 5-6 million doses of Sputnik V per month in June-July
https://tass.com/economy/1274415
Biocad, a Russian biotech company, has reached a monthly production of two million doses of the Sputnik V vaccine. It is expected that the company will ramp up production to produce between five and six million doses per month during the summer, Deputy Director General Alexey Torgov told TASS.
Russia’s Geropharm will start to produce insulin in Venezuela
The government of Venezuela and Russian company Gerofarm have concluded an agreement on long-term cooperation, which involves the localization of insulin production in the Bolivarian Republic.
EU regulator to probe ethical standards of Sputnik vaccine trials: FT
https://www.ft.com/content/50031165-1f46-446b-be9a-36d553805fec
The EU drug regulator will begin investigations next week on whether clinical trials of Russia’s Sputnik V COVID-19 vaccine followed global clinical and scientific guidelines, the Financial Times reported.
Russian drugmakers bypass Gilead to unveil COVID-19 generic
Russian pharmaceutical company Pharmsynthez has allegedly started producing a generic version of COVID-19 drug Remdesivir without the authorization of the drug’s patent owner, Gilead Sciences.
Russia’s EpiVacCorona Vaccine Develops Antibodies in 94 Percent of Senior Citizens, Developer Says
As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia’s EpiVacCorona vaccine, the head of the Yekaterinburg department of Russia’s Vector research institute that developed the vaccine said on Wednesday.
Russia Delays Approving Chinese Vaccine to Favor Homegrown Shots
Russian officials have slowed the authorization of China’s CanSino Biologics Inc.’s Covid-19 vaccine, the only foreign inoculation that is undergoing domestic testing, as they’re confident they can vaccinate the public using homegrown shots.
